Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients

Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy.

Echinocandins are a novel class of antifungal drugs that target beta (1, 3)-D-glucan synthesis. Animal studies have shown that these agents have activity against Pneumocystis jiroveci infection; however, clinical data are lacking. We reviewed all cases of proven P. jiroveci pneumonia (PCP) in non-human immunodeficiency virus-infected patients at our hospital over a 5 year period (2001-2005). Tw...

Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab.

Rituximab enhances treatment efficacy of B-lineage lymphoma by targeting CD20+ B-cells. Such target therapies may compromise the immune system and render patients susceptible to opportunistic infections. We report 2 cases of lymphoma complicated with Pneumocystis jiroveci (previously known as P. carinii) pneumonia (PCP) while being treated with rituximab-containing chemotherapy regimens. In bot...

Pneumocystis jiroveci pneumonia prophylaxis is a challenge in granulomatosis with polyangiitis patients treated with rituximab

Radiological presentation of Pneumocystis jiroveci pneumonia mimicking bacterial pneumonia.

To cite: Langevin B, Saleh M. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2016215207 DESCRIPTION Atypical radiological presentations of Pneumocystis jiroveci pneumonia have been previously reported in non-HIV as well as in HIV-infected patients. We present the case of a 64-year-old woman with a history of left upper lobe small cell lung cancer in radiological ...

ABVD or BEACOPP for Advanced Hodgkin Lymphoma.

The development of multiagent chemotherapy dramatically changed the prognosis of patients with advanced-stage Hodgkin lymphoma (HL). Although almost all of these patients died when treated with radiotherapy or single-agent chemotherapy, the fourdrug regimen MOPP (mustargen, oncovin, procarbazine, and prednisone) led to remission rates of more than 50% and an overall survival (OS) rate of more t...